`
`
`
`Filed: September 29, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`
`
`MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
`INC. and AKORN INC.,1
`Petitioner,
`
`v.
`
`ALLERGAN, INC.
`Patent Owner.
`
`_____________________________
`
`Case IPR2016-01127 (US 8,685,930 B2)
`Case IPR2016-01128 (US 8,629,111 B2)
`Case IPR2016-01129 (US 8,642,556 B2)
`Case IPR2016-01130 (US 8,633,162 B2)
`Case IPR2016-01131 (US 8,648,048 B2)
`Case IPR2016-01132 (US 9,248,191 B2)
`_____________________________
`
`PETITIONERS’ NOTICE OF OBJECTION TO EVIDENCE
`
`
`1 Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-
`00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599,
`IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601,
`have respectively been joined with the captioned proceedings. The word-for-word
`identical paper is filed in each proceeding identified in the caption pursuant to the
`Board’s Scheduling Order (Paper 10).
`
`
`
`
`
`
`
`
`
`I.
`II.
`
`TABLE OF CONTENTS
`
`Objections to EX2100, EX2101, EX2102, and any
`
`INTRODUCTION ........................................................................................ 1
`OBJECTIONS .............................................................................................. 1
`1.
`Reference to/Reliance Thereon ................................................. 1
`2.
`Reference to/Reliance Thereon ................................................. 2
`3.
`Thereon ..................................................................................... 3
`III. CONCLUSION ............................................................................................ 3
`
`Objections to EX2086, EX2087 and EX2103, and any
`
`Objections to URLs, and any Reference to/Reliance
`
`
`
`
`-i-
`
`
`
`
`
`I.
`
`INTRODUCTION
`
`Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioners submit the following
`
`objections to Exhibits 2086, 2087 and 2100-2103 as listed on each List of Exhibits
`
`filed by the St. Regis Mohawk Tribe (“SRMT”) and two unlisted URLs in its
`
`motion to dismiss (“Motion”), and any reference to or reliance on the foregoing
`
`Exhibits in SRMT filings. As required by 37 C.F.R. §42.62, Petitioners’ objections
`
`below apply the Federal Rules of Evidence (“F.R.E.”).
`
`II. OBJECTIONS
`1. Objections to EX2100, EX2101, EX2102, and any Reference
`to/Reliance Thereon
`
`Grounds for Objection: F.R.E. 402 (Relevance); 403 (Prejudice); 801, 802,
`
`803, 805 (Inadmissible Hearsay).
`
`SRMT describes EX2100 as “National Congress of American Indians,
`
`Current Tax Needs in Indian Country”; EX2101 as “National Congress of
`
`American Indians, Securing Our Futures”; and EX2102 as “National Congress of
`
`American Indians, Taxation”.
`
`SRMT relies on these exhibits to provide critiques of the impacts of Federal
`
`taxation and development policies on Tribes. The Board has no power to address
`
`these policies, any remedy must come from Congress. The exhibits have no
`
`relevance to patent law or to any issue properly before the Board for decision.
`
`Instead, SRMT provides the exhibits to evoke sympathy. Assuming arguendo the
`
`
`-1-
`
`
`
`truth of the statements in the exhibits and the justification of the critiques,
`
`sympathy for SRMT or Tribes generally is not a basis for dismissal under
`
`chapter 31 of the Patent Code (35 U.S.C.). EX2100, EX2101 and EX2102 are
`
`inadmissible under F.R.E. 402 and under F.R.E. 403.
`
`Additionally, these exhibits are not testimony, yet SRMT relies on their
`
`statements to prove the truth of the matter asserted. These exhibits are thus used to
`
`provide hearsay statements without exception. To the extent SRMT relies on
`
`EX2100, EX2101 and EX2102, or on any statements in them for the truth of the
`
`matter asserted, such statements are inadmissible hearsay. F.R.E. 801, 802, 803,
`
`805.
`
`2. Objections to EX2086, EX2087 and EX2103, and any
`Reference to/Reliance Thereon
`
`Grounds for Objection: F.R.E. 106 (Incomplete Writing).
`
`SRMT describes EX2086 as an “Assignment Agreement (Long form)”;
`
`EX2087 as a “Patent License Agreement”; and EX2103 as a recorded assignment
`
`of the involved patents.
`
`Each of these exhibits individually, and all three in combination, is an
`
`incomplete representation of the totality of transactions between SRMT and
`
`Allergan affecting the involved patents. In fairness, all of the documents reflecting
`
`the scope and nature of the transactions between SRMT and Allergan affecting the
`
`involved patents must be considered together. F.R.E. 106.
`
`-2-
`
`
`
`3. Objections to URLs, and any Reference to/Reliance Thereon
`
`Grounds for Objection: F.R.E. 802 (Inadmissible Hearsay).
`
`In the Motion, SRMT cites two URLs without providing corresponding
`
`exhibits: https://www.srmt-nsn.gov/about-the-tribe and https://www.srmt-
`
`nsn.gov/economic-development.
`
`To the extent SRMT relies on these URLs or on any statements in these
`
`URLs for the truth of the matter asserted, such statements are inadmissible hearsay.
`
`F.R.E. 801, 802, 803, 805.
`
`
`III. CONCLUSION
`
`The aforementioned exhibits and URLs are not admissible for the reasons
`
`stated above.
`
`
`
`Dated: September 29, 2017
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee
` Reg. No. 31,990
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-3-
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`This is to certify that I caused to be served a true and correct copy of the
`
`foregoing Petitioners’ Notice of Objection to Evidence, on this 29th day of
`
`September, 2017, on Allergan and St. Regis Mohawk Tribe at the correspondence
`
`address of Allergan and St. Regis Mohawk Tribe as follows:
`
`Dorothy P. Whelan
`Michael Kane
`Susan Morrison Colletti
`Robert M. Oakes
`Jonathan Singer
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`
`Alfonso Chan
`Joseph DePumpo
`Michael W. Shore
`Christopher L. Evans
`Shore Chan DePumpo LLP
`901 Main Street, Suite 3300
`Dallas, TX 75201
`Email: achan@shorechan.com
`Email: jdepumpo@shorechan.com
`Email: mshore@shorechan.com
`Email: cevans@shorechan.com
`
`
`-4-
`
`
`
`Marsha K. Schmidt
`14928 Perrywood Drive
`Burtonsville, MD 20866
`Email: marsha@mkschmidtlaw.com
`
`And on the remaining petitioners as follows:
`
`
`Gary Speier
`Mark Schuman
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST & SCHUMAN, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncaspers.com
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`
`Michael Dzwonczyk
`Azadeh Kokabi
`Travis Ribar
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Email: mdzwonczyk@sughrue.com
`Email: akokabi@sughrue.com
`Email: tribar@sughrue.com
`Attorneys for Akorn Inc.
`
`
`
`Dated: September 29, 2017
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`-5-
`
`